A citation-based method for searching scientific literature

Ionut-Gabriel Funingana, Marika A V Reinius, Angelica Petrillo, Joo Ern Ang, James D Brenton. Semin Cancer Biol 2021
Times Cited: 5







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments.
Claudia Marchetti, Francesca De Felice, Alessia Romito, Valentina Iacobelli, Carolina Maria Sassu, Giacomo Corrado, Caterina Ricci, Giovanni Scambia, Anna Fagotti. Semin Cancer Biol 2021
2
100

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
40

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
413
40

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
40

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu,[...]. Cancer Discov 2017
226
40

Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
119
40

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
643
40

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
402
40

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
638
40

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.
Arielle L Heeke, Michael J Pishvaian, Filipa Lynce, Joanne Xiu, Jonathan R Brody, Wang-Juh Chen, Tabari M Baker, John L Marshall, Claudine Isaacs. JCO Precis Oncol 2018
134
40

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
743
40

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Maddison Rose, Joshua T Burgess, Kenneth O'Byrne, Derek J Richard, Emma Bolderson. Front Cell Dev Biol 2020
82
40


The forefront of ovarian cancer therapy: update on PARP inhibitors.
M R Mirza, R L Coleman, A González-Martín, K N Moore, N Colombo, I Ray-Coquard, S Pignata. Ann Oncol 2020
76
20

Does the "Devil" originate from the fallopian tubes?
Khalid El Bairi, Ouissam Al Jarroudi, Cécile Le Page, Said Afqir. Semin Cancer Biol 2021
4
25


Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.
Alia Ghoneum, Sameh Almousa, Bailey Warren, Ammar Yasser Abdulfattah, Junjun Shu, Hebatullah Abouelfadl, Daniela Gonzalez, Christopher Livingston, Neveen Said. Semin Cancer Biol 2021
7
20

Targeting the tumour microenvironment in platinum-resistant ovarian cancer.
M Cummings, C Freer, N M Orsi. Semin Cancer Biol 2021
1
100

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
William P Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael Bookman, Monica Brown Jones, Jung-Min Lee, Stéphanie Lheureux, Joyce F Liu,[...]. J Clin Oncol 2020
60
20

Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise Wilhite, Santanu Dasgupta, Rodney Paul Rocconi, Ajay Pratap Singh. Semin Cancer Biol 2021
5
20

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.
Marco Petrillo, Giulio Sozzi, Margherita Dessole, Giampiero Capobianco, Salvatore Dessole, Massimo Madonia, Pier Luigi Cherchi, Anna Maria Paoletti, Giovanni Scambia, Vito Chiantera. Semin Cancer Biol 2021
3
33

Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition.
Yael Cohen-Sharir, James M McFarland, Mai Abdusamad, Carolyn Marquis, Sara V Bernhard, Mariya Kazachkova, Helen Tang, Marica R Ippolito, Kathrin Laue, Johanna Zerbib,[...]. Nature 2021
25
20

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
George Somlo, Paul H Frankel, Banu K Arun, Cynthia X Ma, Agustin A Garcia, Tessa Cigler, Leah V Cream, Harold A Harvey, Joseph A Sparano, Rita Nanda,[...]. Clin Cancer Res 2017
63
20

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
114
20

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Tesa M Severson, Denise M Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C Schouten, Suet-Feung Chin, Ian J Majewski, Magali Michaut, Astrid Bosma,[...]. Breast Cancer Res 2017
37
20

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
A Llop-Guevara, S Loibl, G Villacampa, V Vladimirova, A Schneeweiss, T Karn, D-M Zahm, A Herencia-Ropero, P Jank, M van Mackelenbergh,[...]. Ann Oncol 2021
7
20

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
Wanjuan Yang, Jorge Soares, Patricia Greninger, Elena J Edelman, Howard Lightfoot, Simon Forbes, Nidhi Bindal, Dave Beare, James A Smith, I Richard Thompson,[...]. Nucleic Acids Res 2013
20

Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer. JAMA 2019
20

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Ghulam Rehman Mohyuddin, Muhammad Aziz, Alec Britt, Lee Wade, Weijing Sun, Joaquina Baranda, Raed Al-Rajabi, Anwaar Saeed, Anup Kasi. BMC Cancer 2020
23
20

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
86
20

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
120
20

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
20

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
910
20

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020
79
20

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
297
20

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Nadine M Tung, Mark E Robson, Steffen Ventz, Cesar A Santa-Maria, Rita Nanda, Paul K Marcom, Payal D Shah, Tarah J Ballinger, Eddy S Yang, Shaveta Vinayak,[...]. J Clin Oncol 2020
92
20

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
20

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
P A Fasching, T Link, J Hauke, F Seither, C Jackisch, P Klare, S Schmatloch, C Hanusch, J Huober, A Stefek,[...]. Ann Oncol 2021
23
20

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
358
20

Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Breast Cancer Res 2020
176
20

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Christopher J Lord, Andrew N J Tutt, Alan Ashworth. Annu Rev Med 2015
301
20

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
53
20

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Anneleen Daemen, Denise M Wolf, James E Korkola, Obi L Griffith, Jessica R Frankum, Rachel Brough, Lakshmi R Jakkula, Nicholas J Wang, Rachael Natrajan, Jorge S Reis-Filho,[...]. Breast Cancer Res Treat 2012
51
20

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
324
20

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
403
20

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Mallika S Dhawan, Imke H Bartelink, Rahul Raj Aggarwal, Jim Leng, Jenna Z Zhang, Nela Pawlowska, Manuela Terranova-Barberio, Jennifer A Grabowsky, Andrew Gewitz, Amy J Chien,[...]. Clin Cancer Res 2017
39
20

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
23
20

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
Jennifer K Litton, Marion E Scoggins, Kenneth R Hess, Beatriz E Adrada, Rashmi K Murthy, Senthil Damodaran, Sarah M DeSnyder, Abenaa M Brewster, Carlos H Barcenas, Vicente Valero,[...]. J Clin Oncol 2020
69
20

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, Christina Yau, Laura J van 't Veer, Meredith B Buxton, Michael Hogarth, Nola M Hylton, Melissa Paoloni, Jane Perlmutter,[...]. N Engl J Med 2016
319
20

Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Khanh T Do, Bose Kochupurakkal, Sarah Kelland, Adrienne de Jonge, Jennifer Hedglin, Allison Powers, Nicholas Quinn, Courtney Gannon, Loan Vuong, Kalindi Parmar,[...]. Clin Cancer Res 2021
13
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.